Hsbc Holdings PLC Acquires New Stake in PROCEPT BioRobotics Corporation $PRCT

Hsbc Holdings PLC bought a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 160,586 shares of the company’s stock, valued at approximately $3,626,000. Hsbc Holdings PLC owned 0.28% of PROCEPT BioRobotics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of PRCT. Versant Capital Management Inc increased its position in shares of PROCEPT BioRobotics by 994.5% during the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after purchasing an additional 1,084 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after buying an additional 746 shares during the last quarter. Center for Financial Planning Inc. bought a new stake in PROCEPT BioRobotics during the fourth quarter valued at approximately $40,000. Cache Advisors LLC bought a new stake in PROCEPT BioRobotics during the first quarter valued at approximately $42,000. Finally, Essential Partners LLC raised its holdings in PROCEPT BioRobotics by 7,071.4% in the 1st quarter. Essential Partners LLC now owns 2,008 shares of the company’s stock worth $50,000 after purchasing an additional 1,980 shares during the period. 89.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Evercore set a $23.00 price objective on PROCEPT BioRobotics in a research note on Wednesday, August 5th. Piper Sandler cut their price objective on PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, August 5th. Citigroup lowered shares of PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. William Blair cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Finally, TD Cowen lowered their price target on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Hold” and an average target price of $28.00.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms, including Kaplan Fox, Rosen Law Firm and Hagens Berman, announced or reiterated that a securities class action has been filed on behalf of investors who purchased PROCEPT shares from February 28, 2024, through February 25, 2026. Investors seeking to serve as lead plaintiff must act by September 22, 2026. Kaplan Fox class-action notice
• Negative Sentiment: The complaint reportedly alleges that PROCEPT understated weakness in unit handpiece sales and failed to disclose elevated customer inventory, while using repeated late-quarter bulk discounts to pull demand forward. The allegations concern potential violations of federal securities laws and could increase litigation costs, reputational risk and investor uncertainty; they have not been proven in court. Hagens Berman PROCEPT investor alert
• Negative Sentiment: The unusually high number of law-firm solicitations over the past two days keeps attention focused on the lawsuit and the company’s prior sales and inventory disclosures. Although the notices do not introduce a new financial result or regulatory action, continued headlines may weigh on sentiment and limit the stock’s recovery.

Insiders Place Their Bets

In related news, CEO Larry L. Wood acquired 23,900 shares of the business’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $20.85 per share, with a total value of $498,315.00. Following the acquisition, the chief executive officer directly owned 23,900 shares in the company, valued at $498,315. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 1,000 shares of company stock valued at $28,480. Corporate insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Price Performance

NASDAQ:PRCT opened at $20.83 on Friday. The business’s 50-day simple moving average is $20.32 and its two-hundred day simple moving average is $23.93. PROCEPT BioRobotics Corporation has a 52 week low of $16.67 and a 52 week high of $42.43. The stock has a market cap of $1.19 billion, a PE ratio of -10.74 and a beta of 0.89. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The business had revenue of $94.50 million for the quarter, compared to analysts’ expectations of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.35) EPS. As a group, analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.